Ocular Therapeutix, Inc. Overview
Pro stress-test →Ocular Therapeutix is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. The company markets its FDA-approved product DEXTENZA and has a robust pipeline addressing high-burden ophthalmic conditions including retinal diseases.
Strategic Profile
Pro stress-test →The company has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Its lead program AXPAXLI recently demonstrated positive Phase 3 data for wet AMD, a significant advancement in addressing patient burden from frequent injections.
Competitive Landscape
Pro stress-test →Ocular Therapeutix competes in the ophthalmic therapeutics space against larger pharmaceutical companies and specialized biotech firms. Competitors include Novo Nordisk, Clearside Biomedical, Sarepta Therapeutics, Mati Therapeutics, and TearClear. The company's differentiated hydrogel platform for sustained drug delivery provides a competitive advantage over traditional eye drop formulations.
Industry Context
Ocular Therapeutix, Inc. operates in Biopharmaceutical - Ophthalmic Therapeutics.
Key facts
Founded: 2006 · Headquarters: Bedford, Massachusetts, US · Employees: 274 · Revenue: $52M · Market cap: $1.69B